Table 3

Univariate meta-regression results

OutcomeGC, proportion*PDN, daily dose, mgPDN, cumulative dose, 10 gPDN, cumulative dose/year of follow-up, gPar. GC (methylprednisolone), proportion
Changes in SDI Scores0.81
(0.61 to 1.09)
(0.161, 0%)		0.99
(0.92 to 1.07)
(0.827, 0%)		0.90
(0.73 to 1.11)
(0.316, 0.61%)		0.99
(0.86 to 1.13)
(0.840, 0%)		0.76
(0.47 to 1.22)
(0.258, 6.4%)
Cataracts1.04
(0.88 to 1.23)
(0.645, 0%)		1.03
(0.76 to 1.40)
(0.846, 0%)		0.90
(0.57 to 1.43)
(0.659, 0%)		0.96
(0.60 to 1.55)
(0.880, 0%)		0.81
(0.29 to 2.29)
(0.697, 0%)
CVA1.38
(0.97 to 1.98)
(0.075, 22.4%)		0.92
(0.63 to 1.34)
(0.662, 0%)		0.81
(0.31 to 2.10)
(0.666, 0%)		1.21
(0.60 to 2.42)
(0.597, 0%)
MI1.19
(0.84 to 1.69)
(0.337, .8%)		0.92
(0.76 to 1.12)
(0.411, 0%)		1.13
(0.32 to 3.97)
(0.848, 0%)		0.44
(0.14 to 1.41)
(0.167, 33.6%)		1.50
(0.43 to 5.24)
(0.525, 0%)
Overall
CVE		0.86
(0.70 to 1.07)
(0.175, 19.1%)		1.12
(1.02 to 1.24)
(0.019, 100%)		1.43
(0.77 to 2.67)
(0.258, 0%)		1.23
(0.93 to 1.62)
(0.148, 0.7%)		0.86
(0.52 to 1.44)
(0.573, 0%)
Osteonecrosis1.24
(1.02 to 1.51)
(0.033, 11.5%)		1.141.12
(0.97 to 1.34)
(0.118, 0%)		1.67
(1.22 to 2.29)
(0.002, 49.3%)		1.23
(1.12 to 1.34)
(<0.001, 100.0%)		1.71
(0.96 to 3.03)
(0.066, 37.9%)
Osteoporosis and fractures1.09
(0.82 to 1.44)
(0.556, 0%)		1.21
(1.11 to 1.33)
(<0.001, 86.7%)		1.10
(0.63 to 1.89)
(0.743, 0%)		1.33
(0.86 to 2.06)
(0.197, 4.9%)		1.05
(0.74 to 1.50)
(0.770, 0%)

  • Relative risks, confidence intervals (.) and p values plus R2 values (…) for variables with information from three or more studies are presented. Potentially significant effects are bolded for a positive relationship (more drug, more damage) and they are in italics for a negative relationship (lower value, more damage).

  • *Analysed as log odds of proportion.

  • CVA, cerebrovascular accident; CVE, cardiovascular events; GC, glucocorticoids; MI, myocardial infarction; PDN, prednisone; SDI, SLICC Damage Index.